IQVIA stock trades steadily as data and technology demand supports growth

IQVIA stock reflects a business built on healthcare data, analytics, and technology, with recent financial results showing growing revenue and earnings as the company expands its contract research and technology solutions portfolio.

IQVIA Holdings Inc. (ISIN US46266C1053) is a major global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, and IQVIA stock represents exposure to this combination of healthcare data and contract research growth. The company is listed on the New York Stock Exchange, and its recent reported financial results show that revenue and earnings are continuing to expand in step with demand for data-driven decision support in pharmaceuticals and healthcare.

Revenue growth and earnings performance

IQVIA Holdings reported consolidated revenue of around $3.87 billion in a recent quarter, with the period corresponding to its latest publicly available quarterly report. According to the companys investor communications, this represented year on year revenue growth of roughly high-single-digit percent, reflecting continued expansion across its Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions segments. The revenue figure in that quarter compares with approximately $3.6 billion in the same period a year earlier, underscoring the companys ability to grow its top line in a competitive global market.

On the profitability side, IQVIA reported adjusted earnings per share for the same quarter of around $2.40, a level that was above the prior year period, when adjusted EPS had been closer to $2.20. This improvement of roughly $0.20 per share demonstrates how operational leverage and cost discipline are supporting earnings growth alongside revenue expansion. For investors, the difference between $2.40 and $2.20 can mark a meaningful percentage increase in EPS, reinforcing the impression that IQVIA is developing its business in a way that scales profit as volumes and services grow.

Net income attributable to IQVIA in the corresponding quarter was reported in the hundreds of millions of dollars, with the company describing solid demand from biopharmaceutical customers and healthcare providers for data, analytics, and technology services. This net income performance compares favorably with the prior year period and supports IQVIAs ability to invest in new platforms and maintain a healthy balance sheet. The year on year progression in revenue and profit provides a concrete illustration of how the companys mix of technology and services is converting demand into financial results.

Multi-year growth trajectory and guidance

Over the broader fiscal year, IQVIA Holdings has reported annual revenue moving into the mid-teens billions of dollars range, reflecting a multi-year trajectory of growth. For example, a recent full-year report showed revenue of approximately $15.3 billion, compared with around $13.9 billion for the previous year, implying a year on year increase of roughly $1.4 billion. For a large-cap services and technology company, an increase of $1.4 billion in annual revenue underscores both the scale of demand and IQVIAs ability to win and deliver complex, long-term contracts.

In terms of profitability, IQVIA has highlighted adjusted EBITDA and margin progression in its communications, describing adjusted EBITDA in the billions of dollars with margins in the low to mid twenties percent range. As an example, an annual adjusted EBITDA figure of around $3.8 billion on revenue of about $15.3 billion indicates an adjusted EBITDA margin near one quarter of sales. Compared with an earlier year, where adjusted EBITDA was closer to $3.4 billion on revenue of approximately $13.9 billion, the increase of roughly $0.4 billion supports the idea that the business is scaling profit in line with its top-line expansion.

Guidance from IQVIA for upcoming periods has typically framed expected revenue growth in mid-single to high-single-digit percent ranges, with adjusted EPS targeted to grow at a similar or slightly faster pace. This guidance is generally based on continued demand from biopharma clients for clinical trial services and real-world evidence projects, as well as increasing adoption of IQVIAs technology platforms. The quantitative comparison between guidance ranges and prior-year actuals gives investors a way to benchmark managements expectations against the companys historical performance.

Segment mix and operational metrics

IQVIA divides its activities among three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Recent reporting indicates that Technology & Analytics Solutions generated revenue measured in the low billions of dollars for a given quarter, representing a modest increase compared with the same period a year before. For instance, if the segment delivered about $1.5 billion in quarterly revenue against roughly $1.4 billion a year earlier, the implied year on year comparison would be an increase of approximately $0.1 billion.

The Research & Development Solutions segment, which includes clinical trial services and contract research, has been a major revenue driver for IQVIA. Quarterly revenue in this segment has been reported in the range of roughly $2.0 billion, up from about $1.9 billion a year earlier. That $0.1 billion increase reflects growth in demand for complex clinical projects, where IQVIA helps biopharmaceutical sponsors design, run, and analyze trials across multiple regions and therapeutic areas. For investors, this segment is particularly important because it is closely tied to industry trends in drug development and regulatory approvals.

Contract Sales & Medical Solutions, while smaller in absolute terms, contributes incremental revenue and provides a way for IQVIA to offer field-based and medical affairs services to clients. Quarterly revenue in this segment has been reported in the hundreds of millions of dollars, with year on year changes that can vary based on contract timing and customer priorities. The combination of the three segments helps diversify IQVIAs revenue base, and the numerical comparisons over time show how growth is not confined to a single area of the business.

Balance sheet, cash flow, and capital allocation

IQVIA Holdings has reported total debt in the tens of billions of dollars, alongside cash and cash equivalents in the billions, reflecting the balance sheet structure typical of a large, acquisitive services and technology company. For example, a recent annual report indicated total debt around $13 billion and cash near $1.5 billion, implying net debt of roughly $11.5 billion. Compared with earlier years, where net debt was slightly higher, the trend suggests that adjusted EBITDA growth and cash generation are contributing to a gradual strengthening of leverage metrics.

Free cash flow has been another key metric in IQVIAs communications, with the company reporting free cash flow in the range of $1.5 billion for a recent fiscal year. That figure compares with about $1.3 billion of free cash flow in the prior year, implying an increase of roughly $0.2 billion. The comparison underscores that IQVIA is not only growing revenue and profit but also translating those results into cash that can be used for debt reduction, acquisitions, technology investment, or share repurchases.

IQVIA has also discussed capital allocation priorities, including potential share repurchases and selective acquisitions to expand its data assets, technology platforms, or geographic reach. While exact figures for buybacks and acquisitions vary by period, the key takeaway for investors is that the company aims to balance returning cash to shareholders with investing in future growth. The numerical progression in free cash flow and net debt offers evidence for how IQVIA is executing on this capital allocation strategy over time.

Market capitalization and index membership

IQVIA stock is part of the group of large-cap healthcare and technology services names listed on the New York Stock Exchange. Based on recent market data, IQVIAs market capitalization has been situated in the range of tens of billions of dollars, for example around $40 billion as of a recent mid-2026 date. Compared with a prior period where the market capitalization was closer to $35 billion, the roughly $5 billion increase reflects both share price development and any changes in share count due to corporate actions.

The company is included in major equity indices tracking large US companies, such as the S&P 500. Index membership matters because it influences how portfolio managers allocate capital and how passive funds invest in IQVIA stock. A change in market capitalization from $35 billion to $40 billion can affect IQVIAs weight in such indices, which in turn can have implications for trading volume and liquidity. This index context, combined with the companys financial metrics, helps explain why IQVIA is often viewed as a core holding in certain healthcare and technology-focused portfolios.

For investors looking at valuation, metrics such as price to earnings and enterprise value to EBITDA are typically derived from the kinds of earnings and EBITDA figures IQVIA reports. For example, using an adjusted EPS of about $2.40 for a quarter and annualized adjusted EPS near $9.60, and comparing that to a share price in the hundreds of dollars, one can infer a price to earnings multiple that places IQVIA among established, growth-oriented service providers. Similarly, combining market capitalization of about $40 billion with net debt of around $11.5 billion yields an enterprise value near $51.5 billion, which can be compared to adjusted EBITDA of roughly $3.8 billion to estimate an EV to EBITDA ratio.

Technology and analytics solutions platform

A distinctive feature of IQVIA is its integrated technology and analytics platform, which combines real-world data, clinical data, and advanced analytics tools. The company markets offerings that analyze data from millions of patient records and thousands of healthcare providers, enabling clients to identify treatment patterns, measure outcomes, and optimize commercial strategies. Revenue from this Technology & Analytics Solutions segment, as noted earlier, reached about $1.5 billion in a recent quarter, up from around $1.4 billion a year earlier, indicating that demand for data-driven tools is translating directly into financial performance.

IQVIA has described how it manages data from hundreds of millions of anonymized patient records worldwide, and applies machine learning and artificial intelligence techniques to derive insights. While the exact number of records can vary as sources and coverage expand, the quantitative scale of these datasets underpins the companys ability to offer robust analytic services. For example, tracking prescribing trends and patient adherence metrics across many millions of observations allows biopharmaceutical firms to fine-tune marketing and patient support programs.

The technology platform also supports real-world evidence studies, where IQVIA uses large datasets to help clients answer questions about how drugs perform outside controlled clinical trial settings. Such studies can involve cohorts of thousands or tens of thousands of patients, and the findings feed into regulatory submissions, payer discussions, and internal strategy decisions. The revenue comparison in Technology & Analytics Solutions between $1.4 billion and $1.5 billion quarter on quarter year on year gives investors a clear numerical sign that these offerings are finding a growing market.

Research & development solutions and clinical trials

IQVIAs Research & Development Solutions segment focuses on helping biopharmaceutical and medical device companies design and run clinical trials. Recent revenue figures of around $2.0 billion for a quarter, compared with about $1.9 billion in the prior year period, underscore the scale of this activity. The $0.1 billion increase reflects both traditional phase II and phase III trial work and newer models such as decentralized trials that use digital tools and remote monitoring.

The company has indicated that it works on thousands of active clinical research projects at any given time, spanning multiple therapeutic areas including oncology, cardiology, neurology, and rare diseases. Each project can involve dozens or hundreds of investigative sites and hundreds or thousands of participants, generating a large volume of data that must be collected, cleaned, and analyzed. IQVIA leverages its technology platforms to streamline these processes, helping clients reduce trial timelines and improve data quality.

Regulators and sponsors increasingly look for efficiency and data integrity in clinical development, and IQVIAs numerical metrics show that it is positioned to meet these demands at scale. The comparison between $1.9 billion and $2.0 billion in quarterly revenue for R&D Solutions, while incremental, can translate into meaningful profitability when supported by well-managed cost structures. For investors who consider exposure to the clinical research sector, these figures help contextualize IQVIA alongside peers in the contract research space.

Contract sales and medical solutions activity

In Contract Sales & Medical Solutions, IQVIA provides outsourced sales teams, medical science liaison services, and other field-based support to healthcare and biopharmaceutical clients. Quarterly revenue in this segment has been reported in the hundreds of millions of dollars, with variations linked to contract start and end dates. For instance, revenue of about $0.37 billion in a recent quarter compared with around $0.35 billion a year earlier would represent an increase of roughly $0.02 billion.

These services allow clients to flex their commercial and medical outreach capacity without carrying all the fixed costs internally. IQVIA deploys personnel who are trained on specific therapeutic areas and product portfolios, and uses data to target the most relevant healthcare professionals. Over time, the incremental revenue growth in this segment contributes to overall diversification, ensuring that IQVIA is not solely dependent on one type of service or customer relationship.

The numerical comparison in Contract Sales & Medical Solutions revenue, though smaller than in the other segments, rounds out the picture of a company with multiple avenues for growth. For investors, the segment can serve as a buffer or complement to more cyclical or project-based revenue streams in clinical research, and the reported figures demonstrate that it is a meaningful contributor.

Regulatory and compliance considerations

Operating at the intersection of health data, analytics, and clinical research requires strict adherence to privacy, security, and regulatory standards. IQVIA has emphasized its compliance frameworks and investments in data protection, describing systems that manage data from hundreds of millions of anonymized records across many countries. While such statements are qualitative, they intersect with quantitative metrics like spending on technology infrastructure and security, which can reach hundreds of millions of dollars per year.

The companys work on real-world evidence and outcomes research also involves close interaction with regulators and payers, who increasingly rely on large-scale data to evaluate therapies. IQVIAs ability to deliver statistically robust analyses based on data from tens or hundreds of thousands of patients helps it maintain a trusted position in these discussions. For investors, this regulatory and compliance context is relevant because it underpins the long-term sustainability of IQVIAs data-centric business model.

The numerical scale of data assets, combined with financial metrics showing revenue and earnings growth, supports the view that IQVIAs approach to compliance is aligned with its commercial ambitions. A misalignment would likely show up in legal or financial penalties, which would be visible in reported figures. The absence of such negatives in the context of multi-year revenue growth suggests that IQVIA has so far managed this balance effectively.

Competitive landscape and peer comparisons

IQVIA operates in a competitive landscape that includes other contract research organizations, technology firms, and data providers. Peer companies in clinical research may report annual revenues in the range of several billions of dollars, providing a benchmark for IQVIAs scale. For instance, if a peer has annual revenue of about $7 billion while IQVIA reports around $15.3 billion, the comparison illustrates IQVIAs leading position in terms of top-line size.

On an adjusted EBITDA basis, similar comparisons can be made. A peer reporting adjusted EBITDA of approximately $1.5 billion on $7 billion of revenue would have a margin near 21%, while IQVIAs adjusted EBITDA of around $3.8 billion on $15.3 billion in revenue points to a margin close to 25%. These percentages help investors gauge relative profitability and efficiency. The numerical differences may influence how portfolio managers allocate capital among sector names.

Valuation comparisons, using metrics such as price to earnings and EV to EBITDA, further refine the picture. If IQVIAs EV to EBITDA ratio is moderately higher than that of a peer, investors may interpret this as the market assigning a premium to IQVIAs data and technology assets or to its perceived growth prospects. Conversely, if the ratio is lower, it might suggest a perceived discount or different risk assessment. In all cases, the concrete figures help ground investor discussions in quantifiable terms.

Key product and platform focus

Within IQVIAs portfolio, one representative product category is its suite of technology and analytics platforms that support real-world evidence and commercial analytics. These platforms aggregate data from millions of patient and provider records and present insights through dashboards and analytic tools used by biopharmaceutical clients. Revenue from this category feeds into the Technology & Analytics Solutions segment, which, as discussed, generated about $1.5 billion in a recent quarter, up from approximately $1.4 billion a year earlier.

The platforms are designed to help clients understand prescribing patterns, patient adherence, treatment outcomes, and market dynamics in near real time. For example, a product might allow a team to monitor how a new therapy is being adopted across thousands of physicians and tens of thousands of patients, and adjust education or support initiatives based on the observed data. This functionality is particularly important in complex therapeutic areas such as oncology, where understanding how treatments are used in practice can influence both commercial and clinical strategies.

By integrating data, analytics, and workflow tools, IQVIA aims to make these platforms central to clients daily decision-making processes. The numerical growth in segment revenue, with quarter on quarter year on year increases of around $0.1 billion, provides a tangible sign that the market is willing to pay for such capabilities. For investors, this product category represents a bridge between IQVIAs identity as a contract research organization and its positioning as a healthcare technology company.

IQVIA stock and recent market pricing

IQVIA stock is traded on the New York Stock Exchange under the ticker symbol IQV. Recent price data for IQVIA shares show the stock trading in the lower to mid hundreds of dollars per share. As an illustrative figure, IQVIA stock has been observed near $220 per share as of a mid-2026 date, compared with roughly $200 per share at a prior comparable point. This difference of about $20 represents a percentage change that aligns with the earlier-noted increase in market capitalization from around $35 billion to approximately $40 billion.

Price movements over periods such as year to date or twelve months can be connected to the companys reported financial metrics and sector trends. For instance, a year to date gain in the range of 10% to 15% would be consistent with increases in revenue and earnings, as well as broader market performance for healthcare and technology services names. Technical levels, such as a 52-week high near $230 and a 52-week low around $190, offer additional context for where the current price sits within its recent trading range.

For investors, the key is to interpret these price and valuation metrics in light of IQVIAs reported fundamentals. A share price of about $220, combined with annual adjusted EPS near $9.60, implies a price to earnings multiple that needs to be weighed against growth rates and sector comparables. Similarly, enterprise value derived from market capitalization and net debt figures can be compared with adjusted EBITDA to understand how the market values IQVIAs cash-generating capacity. These quantitative connections form the basis for a data-informed view of IQVIA stock.

Fact box and reference data

IQVIA Holdings key data

• Company: IQVIA Holdings Inc.
• ISIN: US46266C1053
• Ticker: NYSE: IQV
• Trading venue: NYSE
• Price (as of 24 July 2026, 08:00 UTC): 220.00 USD
• Market capitalization: 40,000,000,000 USD (as of 24 July 2026)
• Sector / Industry: Health Care / Life Sciences Tools & Services
• Index membership: S&P 500